SAMM50 mediates basal lysosomal degradation of members of the SAM and MICOS complex. (A) Immunoblots of lysates of WT and SAMM50 KD HeLa cells untreated or treated with BafA1 or MG132 for 24 h. (B) Densitometric analysis of protein levels for A from four independent experiments. Values are mean ± SD. **, P < 0.005; *, P < 0.01; †, NS; one-way ANOVA. (C) Diffraction-limited DV microscopic images of WT HeLa cells stained with antibodies to LAMP2 and SAMM50. Arrows indicate colocalization. Scale bars, 10 µm. (D and E) Immunoblots of extracts from WT and ATG7 KO HeLa cells untreated or treated with BafA1 for 24 h (D) and quantified (E). Values are mean ± SD. **, P < 0.005; *, P < 0.01; †, NS; one-way ANOVA. (F) Immunoblots of extracts of WT, SAMM50 KD, and SAMM50 KD cells reconstituted with Myc-SAMM50 untreated or treated with BafA1 for 24 h. (G) Relative protein levels for F from three independent experiments. Values are mean ± SD. ***, P < 0.001; **, P < 0.005; *, P < 0.01; †, NS; one-way ANOVA. (H) Immunoblots of lysates from WT, SAMM50 KD, and SAMM50 KD reconstituted with either Myc-SAMM50 WT or SAMM50 Δ1–125, untreated or treated with BafA1 for 24 h. (I) Relative protein levels for H from three independent experiments. Values are mean ± SD. **, P < 0.005; †, NS; one-way ANOVA.